1. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin
Invest (2012) 122(10):3424–31. doi: 10.1172/jci63186
10. Minagawa K, Katayama Y, Nishikawa S, Yamamoto K, Sada A, Okamura A,
et al. Inhibition of G(1) to s phase progression by a novel zinc finger protein P58(TFL)
at p-bodies. Mol Cancer Res (2009) 7(6):880–9. doi: 10.1158/1541-7786.mcr-08-0511
2. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, et al. The
eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 147
(3):554–64. doi: 10.1016/j.cell.2011.09.035
11. Wawro M, Kochan J, Krzanik S, Jura J, Kasza A. Intact NYN/PIN-like domain is
crucial for the degradation of inflammation-related transcripts by ZC3H12D. J Cell
Biochem (2017) 118(3):487–98. doi: 10.1002/jcb.25665
3. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al.
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of nonHodgkin lymphomas. Blood (2009) 114(12):2467–75. doi: 10.1182/blood-2008-12-194852
12. Minagawa K, Wakahashi K, Kawano H, Nishikawa S, Fukui C, Kawano Y, et al.
Posttranscriptional modulation of cytokine production in T cells for the regulation of excessive
inflammation by TFL. J Immunol (2014) 192(4):1512–24. doi: 10.4049/jimmunol.1301619
4. Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, et al. Genomewide profiling of follicular lymphoma by array comparative genomic hybridization
reveals prognostically significant DNA copy number imbalances. Blood (2009) 113
(1):137–48. doi: 10.1182/blood-2008-02-140616
13. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al.
Genetics and pathogenesis of diffuse Large b-cell lymphoma. N Engl J Med (2018) 378
(15):1396–407. doi: 10.1056/NEJMoa1801445
14. Kawamori Y, Katayama Y, Asada N, Minagawa K, Sato M, Okamura A, et al.
Role for vitamin d receptor in the neuronal control of the hematopoietic stem cell
niche. Blood (2010) 116(25):5528–35. doi: 10.1182/blood-2010-04-279216
5. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, et al.
CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of
malignant b cells. Br J Haematol (2002) 119(2):492–5. doi: 10.1046/j.13652141.2002.03832.x
15. Egle A, Harris AW, Bath ML, O’Reilly L, Cory S. VavP-Bcl2 transgenic mice
develop follicular lymphoma preceded by germinal center hyperplasia. Blood (2004)
103(6):2276–83. doi: 10.1182/blood-2003-07-2469
6. Hussain SK, Zhu W, Chang SC, Breen EC, Vendrame E, Magpantay L, et al.
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor
CXCR5, and HIV-associated non-hodgkin b-cell lymphoma risk. Cancer Epidemiol
Biomarkers Prev (2013) 22(2):295–307. doi: 10.1158/1055-9965.epi-12-1122
16. Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, et al. MCP-induced protein 1
deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling.
J Exp Med (2010) 207(13):2959–73. doi: 10.1084/jem.20092641
7. Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH, et al. A
prospective study of 67 serum immune and inflammation markers and risk of nonHodgkin lymphoma. Blood (2013) 122(6):951–7. doi: 10.1182/blood-2013-01-481077
17. Huang S, Qi D, Liang J, Miao R, Minagawa K, Quinn T, et al. The putative tumor
suppressor Zc3h12d modulates toll-like receptor signaling in macrophages. Cell Signal
(2012) 24(2):569–76. doi: 10.1016/j.cellsig.2011.10.011
18. Sasaki Y, Calado DP, Derudder E, Zhang B, Shimizu Y, Mackay F, et al. NIK
overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces
BAFF : BAFF-r-mediated survival signals in b cells. Proc Natl Acad Sci U.S.A. (2008)
105(31):10883–8. doi: 10.1073/pnas.0805186105
19. Zhang H, Wang WC, Chen JK, Zhou L, Wang M, Wang ZD, et al. ZC3H12D
attenuated inflammation responses by reducing mRNA stability of proinflammatory
genes. Mol Immunol (2015) 67(2 Pt B):206–12. doi: 10.1016/j.molimm.2015.05.018
8. Yamamoto K, Okamura A, Minagawa K, Yakushijin K, Urahama N, Gomyo H,
et al. A novel t(2;6)(p12;q23) appearing during transformation of follicular lymphoma
with t(18;22)(q21;q11) to diffuse large cell lymphoma. Cancer Genet Cytogenet (2003)
147(2):128–33. doi: 10.1016/S0165-4608(03)00201-2
9. Minagawa K, Yamamoto K, Nishikawa S, Ito M, Sada A, Yakushijin K, et al.
Deregulation of a possible tumour suppressor gene, ZC3H12D, by translocation of
IGK@ in transformed follicular lymphoma with t(2;6)(p12;q25). Br J Haematol (2007)
139(1):161–3. doi: 10.1111/j.1365-2141.2007.06752.x
Frontiers in Immunology
12
frontiersin.org
Minagawa et al.
10.3389/fimmu.2023.1197112
20. Wakahashi S, Kawakami F, Wakahashi K, Minagawa K, Matsuo K, Katayama Y, et al.
Transformed follicular lymphoma (TFL) predicts outcome in advanced endometrial cancer.
Cancer Epidemiol Biomarkers Prev (2018) 27(8):963–9. doi: 10.1158/1055-9965.epi-17-0762
cancer. Cancer Immunol Immunother (2018) 67(2):261–9. doi: 10.1007/s00262-0172083-y
30. Weiss JM, Robinet M, Aricha R, Cufi P, Villeret B, Lantner F, et al. Novel
CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in
experimental myasthenia gravis. Oncotarget (2016) 7(7):7550–62. doi: 10.18632/
oncotarget.6885
21. Yang B, Ji LL, Xu HL, Li XP, Zhou HG, Xiao T, et al. Zc3h12d, a novel of
hypomethylated and immune-related for prognostic marker of lung adenocarcinoma.
J Inflamm Res (2021) 14:2389–401. doi: 10.2147/jir.s304278
22. Gong W, Dai W, Wei H, Chen Y, Zheng Z. ZC3H12D is a prognostic biomarker
associated with immune cell infiltration in lung adenocarcinoma. Transl Cancer Res
(2020) 9(10):6128–42. doi: 10.21037/tcr-20-1465
31. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive
bcl-2 expression throughout the hematopoietic compartment affects multiple lineages
and enhances progenitor cell survival. Proc Natl Acad Sci U.S.A. (1999) 96(26):14943–8.
doi: 10.1073/pnas.96.26.14943
23. Huang WQ, Yi KH, Li Z, Wang H, Li ML, Cai LL, et al. DNA Methylation
profiling reveals the change of inflammation-associated ZC3H12D in leukoaraiosis.
Front Aging Neurosci (2018) 10:143. doi: 10.3389/fnagi.2018.00143
32. Cox GW, Mathieson BJ, Giardina SL, Varesio L. Characterization of IL-2
receptor expression and function on murine macrophages. J Immunol (1990) 145
(6):1719–26. doi: 10.4049/jimmunol.145.6.1719
24. Emming S, Bianchi N, Polletti S, Balestrieri C, Leoni C, Montagner S, et al. A
molecular network regulating the proinflammatory phenotype of human memory T
lymphocytes. Nat Immunol (2020) 21(4):388–99. doi: 10.1038/s41590-020-0622-8
33. Fuchs T, Hahn M, Ries L, Giesler S, Busch S, Wang C, et al. Expression of
combinatorial immunoglobulins in macrophages in the tumor microenvironment. PloS
One (2018) 13(9):e0204108. doi: 10.1371/journal.pone.0204108
25. Fu M, Blackshear PJ. RNA-Binding proteins in immune regulation: a focus on CCCH
zinc finger proteins. Nat Rev Immunol (2017) 17(2):130–43. doi: 10.1038/nri.2016.129
34. Racine R, McLaughlin M, Jones DD, Wittmer ST, MacNamara KC, Woodland
DL, et al. IgM production by bone marrow plasmablasts contributes to long-term
protection against intracellular bacterial infection. J Immunol (2011) 186(2):1011–21.
doi: 10.4049/jimmunol.1002836
26. Ryan L, Mills KHG. Sex differences regulate immune responses in experimental
autoimmune encephalomyelitis and multiple sclerosis. Eur J Immunol (2022) 52(1):24–
33. doi: 10.1002/eji.202149589
27. Billi AC, Kahlenberg JM, Gudjonsson JE. Sex bias in autoimmunity. Curr Opin
Rheumatol (2019) 31(1):53–61. doi: 10.1097/bor.0000000000000564
28. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al.
The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).
PloS One (2010) 5(8):e11986. doi: 10.1371/journal.pone.0011986
29. Wei Y, Lin C, Li H, Xu Z, Wang J, Li R, et al. CXCL13 expression is prognostic
and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric
Frontiers in Immunology
35. Pioli KT, Lau KH, Pioli PD. Thymus antibody-secreting cells possess an
interferon gene signature and are preferentially expanded in young female mice.
iScience (2023) 26(3):106223. doi: 10.1016/j.isci.2023.106223
36. Henry RA, Kendall PL. CXCL13 blockade disrupts b lymphocyte organization in
tertiary lymphoid structures without altering b cell receptor bias or preventing diabetes
in nonobese diabetic mice. J Immunol (2010) 185(3):1460–5. doi: 10.4049/
jimmunol.0903710
13
frontiersin.org
...
論文の公開元へ
